New experimental and clinical data on the efficacy of pharmacological magnesium infusions in cerebral infarcts

Magnesium Research

Volumn 11, Issue 1, 1998, Pages 43-56

  Muir, Keith W ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cerebral ischaemia; Cerebro vascular disease; Clinical trial; Magnesium; Stroke

Indexed keywords

MAGNESIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT;

BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; DISEASE MODEL; HUMAN; METABOLISM; MULTICENTER STUDY; PATHOPHYSIOLOGY; REVIEW;

BRAIN ISCHEMIA; CEREBRAL INFARCTION; CEREBROVASCULAR DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; MAGNESIUM; MULTICENTER STUDIES; NEUROPROTECTIVE AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0032018743     PISSN: 09531424     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Marler, J.R., Brott, T., Broderick, J., Kothari, R., ODonoghue, M., Barsan, W., Tomsick, T., Spilker, J., Miller, R., Sauerbeck, L., Farrell, J., Kelly, J., Perkins, T., McDonald, T., Rorick, M., Hickey, C., Armitage, J., Perry, C. and Thalinger, K. (1995): Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333, 1581-1587.
2. Hacke, W., Kaste, M., Fieschi, C., Toni, D., Lesaffre, E., von Kummer, R., Boysen, G., Bluhmki, E., Hoxter, G., Mahagne, M.H. and Hennerici, M. (1995): Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA. 274, 1017-1025.
3. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. (1995): Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 346, 1509-1514.
4. The Multicenter Acute Stroke Trial - Europe Study Group. (1996): Thrombolytic therapy with streptokinase in acute ischemic stroke. N. Engl. J. Med. 335, 145-150.
5. Donnan, G. A., Davis, S.M., Chambers, B.R., Gates, P.C., Hankey, G.J., McNeil, J.J., Rosen, D., Stewart-Wynne, E.G. and Tuck, R.R. (1996): Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 276, 961-966.
6. Morris, A. D., Grosset, D.G., Squire, I.B., Lees, K.R., Bone, I. and Reid, J.L. (1993): The experiences of an acute stroke unit - implications for multicentre acute stroke trials. J. Neurol. Neurosurg. Psych. 56, 352-355.
7. Park, C. K., Nehls, D.G., Graham, D.I., Teasdale, G.M. and McCulloch, J. (1988): The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann. Neurol. 24, 543-551.
8. MacDermott, A. B., Mayer, M.L., Wesbrook, G.L., Smith, S.J. and Barker, J.L. (1986): NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature 321, 519-522.
9. 2+ induced by excitatory amino acids in CA1 hippocampal neurons. Science 240, 649-653.
10. Gill, R., Foster, A.C. and Woodruff, G.N. (1987): Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil. J. Neurosci. 7, 3343-3349.
11. McCulloch, J. (1992): Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man. Br. J. Clin. Pharmacol. 34, 106-114.
12. Gill, R., Nordholm, L. and Lodge, D. (1992): The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischaemia model. Brain Res. 580, 35-43.
13. Bullock, R., Graham, D.I., Swanson, S. and McCulloch, J (1994): Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat. J. Cereb. Blood. Flow. Metab. 14, 466-471.
14. MacKay, K. B., Kusumoto, K., Graham, D.I. and McCulloch, J. (1993): Focal cerebral ischemia in the cat: Pretreatment with a kappa-1 opioid receptor agonist, CI-977. Brain Res. 618, 213-219.
15. Leach, M. J., Swan, J.H., Eisenthal, D., Dopson, M. and Nobbs, M. (1993): BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke 24, 1063-1067.
16. Muir, K. W. and Lees, K.R. (1995): Clinical experience with excitatory amino acid antagonist drugs. Stroke 26, 503-513.
17. Wahlgren, N. G., MacMahon, D.G., DeKeyser, J., Indredavik, B. and Ryman, T. (1994): Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc. Dis. 4, 204-210.
18. Squire, I. B. and Lees, K.R. (1996): Lifarizine in acute stroke study. Cerebrovasc. Dis. 5, 1-2.
19. Diener, H. C., Hacke, W., Hennerici, M., Radberg, J., Hantson, L. and De Keyser, J. (1996): Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial. Lubeluzole International Study Group. Stroke 27, 76-81.
20. Nowak, L., Bregestovski, P., Ascher, P., Herbet, A. and Prochiantz, A. (1984): Magnesium gates glutamate-activated channels in mouse central neurones. Nature 307, 462-465.
21. Ascher, P. and Nowak, L. (1988): The role of divalent cations in the N-methyl-D-aspartate responses of mouse central neurones in culture. J. Physiol. Lond. 399, 247-266.
22. 2+-block site of the NMDA receptor channel. Nature 358, 673-675.
23. Cox, J. A., Lysko, P.G. and Henneberry, R.C.. (1989): Excitatory amino acid neurotoxicity at the N-methyl-D-aspartate receptor in cultured neurons: Role of the voltage-dependent magnesium block. Brain Res. 499, 267-272.
24. 1 and cGMP in cultured neocortical neurons: evidence for distinct regulation of different responses. Neurochem. Int. 25, 301-308.
25. Rose, K., Christine, C.W. and Choi, D.W. (1990): Magnesium removal induces paroxysmal neuronal firing and NMDA receptor-mediated neuronal degeneration in cortical cultures. Neurosci. Lett. 115, 313-317.
26. 2+ and MK-801. Eur. J. Pharmacol. 156, 111-120.
27. Davies, J. and Watkins, J.C. (1977): Effect of magnesium ions on the responses of spinal neurones to excitatory amino acids and acetylcholine. Brain Res. 130, 364-368.
28. Harrison, N. L. and Simmonds, M.A. (1985): Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br. J. Pharmacol. 84, 381-391.
29. Ault, B., Evans, R.H., Francis, A.A., Oakes, D.J. and Watkins, J.C. (1980): Selective depression of excitatory amino acid induced depolarizations by magnesium ions in isolated spinal cord preparations. J. Physiol. Lond. 307, 413-428.
30. 2+ of N-methyl-D-aspartate-activated channels. Biophys. J. 57, 1085-1090.
31. 2+ in cultured cortical neurons. Neuron 11, 751-757.
32. 2+] following human focal cerebral ischemia. Neurology 43, 1577-1581.
33. Brooks, K. J. and Bachelard, H.S. (1989): Changes in intracellular free magnesium during hypoglycaemia and hypoxia in cerebral tissue as calculated from 31P-nuclear magnetic resonance spectra. J. Neurochem. 53, 331-334.
34. Vink, R., McIntosh, T.K., Demediuk, P. and Faden, A.I. (1987): Decrease in total and free magnesium concentration following traumatic brain injury in rats. Biochem. Biophys. Res. Comm. 149, 594-599.
35. Bowe, M. A. and Nadler, J.V. (1990): Developmental increase in the sensitivity to magnesium of NMDA receptors on CA1 hippocampal pyramidal cells. Dev. Brain Res. 56, 55-61.
36. Strecker, G. J., Jackson, M.B. and Dudek, F.E. (1994): Blockade of NMDA-activated channels by magnesium in the immature rat hippocampus. Journal of Neurophysiology 72, 1538-1548.
37. Kutsuwada, T., Kashiwabuchi, N., Mori, H., Sakimura, K., Kushiya, E., Araki, K., Meguro, H., Masaki, H., Kumanishi, T. and Arakawa, M. (1992): Molecular diversity of the NMDA receptor channel. Nature 358, 36-41.
38. Hori, N. and Carpenter, D.O. (1994): Functional and morphological changes induced by transient in vivo ischemia. Exp. Neurol. 129, 279-289.
39. 2+ block of NMDA-receptor channels as a mechanism of modulation. Nature 356, 521-523.
40. Graham, E. M., Apostolou, M. Mishra, O.P. and Delivoria-Papadopoulos, M. (1996): Modification of the N-methyl-D-aspartate (NMDA) receptor in the brain of newborn piglets following hyperventilation induced ischemia. Neurosci. Lett. 218, 29-32
41. Rothman, S. M. (1983): Synaptic activity mediates death of hypoxic neurons. Science 220, 536-537.
42. Rothman, S. (1984): Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J. Neurosci. 4, 1884-1891.
43. Smith, D. A. S., Connick, J.H. and Stone, T.W. (1989): Effect of changing extracellular levels of magnesium on spontaneous activity and glutamate release in the mouse neocortical slice. Br. J. Pharmacol. 97, 475-482.
44. Bartrup, J. T. and Stone, T.W. (1988): Presynaptic actions of adenosine are magnesium-dependent. Neuropharmacology 27, 761-763.
45. Clark, G. D. and Rothman, S.M. (1987): Blockade of excitatory amino acid receptors protects anoxic hippocampal slices. Neuroscience 21, 665-671.
46. Kass, I. S., Cottrell, J.E. and Chambers, G. (1988): Magnesium and cobalt, not nimodipine, protect neurons against anoxic damage in the rat hippocampal slice. Anesthesiology 69, 710-715.
47. Schanne, F. A. X., Gupta, R.K. and Stanton, P.K. (1993): 31P-NMR study of transient ischemia in rat hippocampal slices in vitro. Biochim. Biophys. Acta 1158, 257-263.
48. Eimerl, S. and Schramm, M. (1994): The quantity of calcium that appears to induce neuronal death. J. Neurochem. 62, 1223-1226.
49. Choi, D. W. (1985): Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci. Lett. 58, 293-297.
50. Iseri, L. T. and French, J.H. (1984): Magnesium, nature's physiologic calcium blocker. Am. Heart J. 108, 188-193.
51. Favaron, M. and Bernardi, P. (1985): Tissue-specific modulation of the mitochondrial calcium uniporter by magnesium ions. FEBS Letters 183, 260-264.
52. 2+ ATPase. J. Neurochem. 68, 1124-1134.
53. 2+ exchanger. J. Neurosci. 12, 430-439.
54. Stys, P. K., Ransom, B.R. and Waxman, S.G. (1990): Effects of polyvalent cations and dihydropyridine calcium channel blockers on recovery of CNS white matter from anoxia. Neurosci. Lett. 115, 293-299.
55. 2+ influx during anoxia in mammalian central nervous system white matter. Ann. Neurol. 30, 375-380.
56. Mroczek, W. J , Lee, W.R. and Davidov, M.E. (1977): Effect of magnesium sulfate on cardiovascular hemodynamics. Angiology 28, 720-724.
57. Reinhart, R. A. (1991): Clinical correlates of the molecular and cellular actions of magnesium on the cardiovascular system. Am. Heart J. 121, 1513-1521.
58. Chi, O. Z., Pollak, P. and Weiss, H.R. (1990): Effects of magnesium sulfate and nifedipine on regional cerebral blood flow during middle cerebral artery ligation in the rat. Arch. Int. Pharmacodyn Ther. 304, 196-205.
59. Grogaard, B., Gerdin, B. and Arfors, K.E. (1988): Inability of flunarizine, lidoflazine or magnesium to counteract delayed hypoperfusion after forebrain ischaemia in the rat. Acta Neurochir. Wien 95, 136-142.
60. Kemp, P. A., Gardiner, S.M., Bennett, T. and Rubin, P.C. (1993): Magnesium sulphate reverses the carotid vasoconstriction caused by endothelin-I, angiotensin II and neuropeptide-Y, but not that caused by N(G)-nitro-L-arginine methyl ester, in conscious rats. Clin. Sci. 85, 175-181.
61. Kemp, P., Gardiner, S.M., Bennett, T. and Rubin, P.C. (1992): Magnesium sulphate reverses cerebral vasoconstriction. J. Hypertens. 10, 1427.
62. 2+ on endothelin-1- and 5-hydroxytryptamine-elicited responses in goat cerebrovascular bed. J. Cardiovasc. Pharmacol. 23, 1004-1010.
63. 2+ in isolated human cerebral arteries. Eur. J. Pharmacol. 229, 83-89.
64. Huang, Q. F., Gebrewold, A., Zhang, A., Altura, B.T. and Altura, B.M. (1994): Role of excitatory amino acids in regulation of rat pial microvasculature. Am. J. Physiol. 266, R158-63.
65. Ram, Z., Sadeh, M., Shacked, I., Sahar, A. and Hadani, M. (1991): Magnesium sulfate reverses experimental delayed cerebral vasospasm after sub-arachnoid hemorrhage in rats. Stroke 22, 922-927.
66. Tamura, A., Graham, D.I., McCulloch, J. and Teasdale, G.M. (1981): Focal cerebral ischaemia in the rat:1 Description of technique and early neuropathological consequences folowing middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 1, 53-60.
67. Izumi, Y., Roussel, S., Pinard, E. and Seylaz, J. (1991): Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats. J. Cereb. Blood Flow Metab. 11, 1025-1030.
68. Roussel, S., Pinard, E. and Seylaz, J. (1992): Effect of MK-801 on focal brain infarction in normotensive and hypertensive rats. Hypertension 19, 40-46.
69. Marmov, M. B., Harbaugh, K.S., Hoopes, P.J., Pikus, H.J. and Harbaugh, R.E. (1996): Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. J. Neurosurg. 85, 117-124.
70. Nishio, A., Gebrewold, A., Altura, B.T. and Altura, B.M. (1988): Comparative effects of magnesium salts on reactivity of arterioles and venules to constrictor agents: an in situ study on microcirculation. J. Pharmacol. Exp. Ther. 246, 859-865.
71. Roffe, C., Thomas, L., Fotheringham, A. and Davies, I. (1996): The effect of magnesium on infarct size and oedema after middle cerebral artery occlusion. Cerebrovasc. Dis. 6 (supplement 2), 42 (Abstract).
72. Blair, J. L., Warner, D S. and Todd, M.M. (1989): Effects of elevated plasma magnesium versus calcium on cerebral ischemic injury in rats. Stroke 20, 507-512.
73. Schmid-Elsaesser, R., Zausinger, S., Hungerhuber, E., Baethmann, A. and Reulen, H. (1997): Additive neuroprotective effects of magnesium and tirilazad in rats subjected to transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 17, S103 (Abstract).
74. Sjostrom, L. G. and Wester, P. (1994): Systemically induced hypermagnesemia increases the bioavailability of magnesium in rat brain. Soc. Neurosci. 20, 181 (Abstract).
75. McDonald, J. W., Silverstein, F.S. and Johnston, M.V. (1989): Neuroprotective effects of MK-801, TCP, PCP and CPP against N-methyl-D-aspartate induced neurotoxicity in an in vivo perinatal rat model. Brain Res. 490, 33-40.
76. McDonald, J. W., Silverstein, F.S., Cardona, D., Hudson, C., Chen, R. and Johnston, M.V. (1990): Systemic administration of MK-801 protects against N-methyl-D-aspartate- and quisqualate-mediated neurotoxicity in perinatal rats. Neuroscience 36, 589-599.
77. McDonald, J. W., Silverstein, F.S. and Johnston, M.V. (1990): Magnesium reduces N-methyl-D-aspartate (NMDA)-mediated brain injury in perinatal rats. Neurosci. Lett. 109, 234-238.
78. 2+ administered up to twenty-four hours following reperfusion prevents ischemic damage of the CA1 neurons in the rat hippocampus. Neuroscience 44, 335-341.
79. Ghribi, O., Callebert, J., Verrecchia, C., Plotkine, M. and Boulu, R.G. (1995): Blockers of NMDA-operated channels decrease glutamate and aspartate extracellular accumulation in striatum during forebrain ischaemia in rats. Fundam. Clin. Pharmacol. 9, 141-146.
80. Thordstein, M., Bagenholm, R., Thiringer, K. and Kjellmer, I. (1993): Scavengers of free oxygen radicals in combination with magnesium ameliorate perinatal hypoxic-ischemic brain damage in the rat. Pediatr. Res. 34, 23-26.
81. Follis, F., Miller, K., Scremin, O.U., Pett, S., Kessler, R. and Wernly, J. (1994): NMDA receptor blockade and spinal cord ischemia due to aortic cross clamping in the rat model. Can. J. Neurol. Sci. 21, 227-232.
82. ++ protect against irreversible damage during CNS ischemia. Stroke 15, 695-698.
83. 1 in alcohol-induced hemorrhagic stroke in a rat model: a 31P-NMR in vivo study. Alcohol 12, 131-136.
84. Huang, Q. F., Gebrewold, A., Altura, B.T. and Altura, B.M. (1990): Magnesium ions prevent phencyclidine-induced cerebrovasospasms and rupture of cerebral microvessels: direct in-vivo microcirculatory studies on the rat brain. Neurosci. Lett. 113, 115-119.
85. 2+ in cerebral vascular smooth muscle cells. Eur. J. Pharmacol. 246, 299-301.
86. McIntosh, T. K., Vink, R., Yamakami, I. and Faden, A.I. (1989): Magnesium protects against neurological deficit after brain injury. Brain Res. 482, 252-260.
87. Smith, D. H., Okiyama, K., Gennarelli, T.A. and McIntosh, T.K. (1993): Magnesium and ketamine attenuate cognitive dysfunction following experimental brain injury. Neurosci. Lett. 157, 211-214.
88. Okiyama, K., Smith, D.H., Gennarelli, T.A., Simon, R.P., Leach, M. and McIntosh, T.K. (1995): The sodium channel blocker and glutamate release inhibitor BW1003C87 and magnesium attenuate regional cerebral edema following experimental brain injury in the rat. J. Neurochem. 64, 802-809.
89. Woods, K. L. and Fletcher, S. (1994): Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 343, 816-819.
90. ISIS-4 Collaborative Group. (1995): ISIS-4:a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 345, 669-685.
91. Lazard, E. M. (1933): An analysis of 575 cases of eclamptic and pre-eclamptic toxemias treated by intravenous injections of magnesium sulphate. Am. J. Obstet. Gynecol. 26, 647-656.
92. Sibai, B. M. (1990): Magnesium sulfate is the ideal anticonvulsant in preeclampsia-eclampsia. Am. J. Obstet. Gynecol. 162, 1141-1145.
93. Lucas, M. J., Leveno, K.J. and Cunningham, F.G. (1995): A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N. Engl. J. Med. 333, 201-205.
94. The Eclampsia Trial Collaborative Group. (1995): Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 345, 1455-1463.
95. Hallak, M., Berman, R.F., Irtenkauf, S.M., Evans, M.I. and Cotton, D.B. (1992): Peripheral magnesium sulfate enters the brain and increases the threshold for hippocampal seizures in rats. Am. J. Obstet. Gynecol. 167, 1605-1610.
96. Fong, J., Gurewitsch, E.D., Volpe, L., Wagner, W.E., Gomilllon, M.C. and August, P. (1995): Baseline serum and cerebrospinal fluid magnesium levels in normal pregnancy and preeclampsia Obstet. Gynecol. 85, 444-448.
97. Thurnau, G. R., Kemp, D.B. and Jarvis, A. (1987): Cerebrospinal fluid levels of magnesium in patients with preeclampsia after treatment with intravenous magnesium sulfate: A preliminary report. Am. J. Obstet. Gynecol. 157, 1435-1438.
98. Belfort, M. A., Saade, G.R. and Moise, Jr. K.J. (1993): The effect of magnesium sulfate on maternal and fetal blood flow in pregnancy-induced hypertension. Acta Obstet. Gynecol. Scand. 72, 526-530.
99. Belfort, M. A., Saade, G.R. and Moise, Jr. K.J. (1992): The effect of magnesium sulfate on maternal retinal blood flow in preeclampsia: A randomized placebo-controlled study. Am. J. Obstet. Gynecol. 167, 1548-1553.
100. Wester, P. O., Asplund, K., Eriksson, S., Hagg, E., Lithner, F. and Strand, T. (1984): Infusion of magnesium in patients with acute brain infarction. Acta Neurol. Scand. 70, 143. (Abstract).
101. Muir, K. W. and Lees, K.R. (1995): A randomised, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke 26, 183-188.
102. Muir, K. W. and Lees, K.R. (1995): Dose-ranging study of magnesium sulphate after acute stroke. Eur. J. Neurol. 2, 7-8. (Abstract).
103. Meden, P., Overgaard, K., Sereghy, T. and Boysen, G. (1993): Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolic stroke model. J. Neurol. Sci. 119, 209-216.
104. Sereghy, T., Overgaard, K. and Boysen, G. (1993): Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats. Stroke 24, 1702-1708.
105. Grieco, G., d'Hollosy, M., Culliford, A.T. and Jonas, S. (1996): Evaluating neuroprotective agents for clinical anti-ischemic benefit using neurological and neuropsychological changes after cardiac surgery under cardiopulmonary bypass. Methodological strategies and results of a double-blind, placebo-controlled trial of GM1 ganglioside. Stroke 27, 858-874.